Please ensure Javascript is enabled for purposes of website accessibility

Why CRISPR Therapeutics Gained 13.4% in April

By George Budwell – May 8, 2019 at 8:27AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CRISPR and partner Vertex bagged an important regulatory designation for CTX001 last month.

What happened

Shares of the gene-editing upstart CRISPR Therapeutics AG (CRSP -2.79%) rose by a market-beating 13.4% in April, according to data from S&P Global Market Intelligence. The biotech's stock perked up after the company announced that the Food and Drug Administration (FDA) granted fast track designation for CTX001 for the treatment of transfusion-dependent beta thalassemia (TDT).

CRISPR is codeveloping CTX001 with Vertex Pharmaceuticals (VRTX -1.88%) as a treatment for both TDT and sickle cell disease. The pair became the first in history to initiate a company-sponsored human trial for a CRISPR-based product when CTX001's early stage trial for TDT kicked off last February.

A cell floating in blood with strands of DNA nearby.

Image Source: Getty Images.

So what

Fast track status permits a drug developer more frequent interactions with the FDA and may open the door to an accelerated review, depending on the data. So this regulatory win is a step in the right direction for CRISPR and Vertex.

That said, there are plenty of experimental drugs and therapies that receive this regulatory designation that either end up going nowhere in clinical studies or get rejected by the agency during their initial review. As a result, CRISPR's double-digit move on this regulatory news probably wasn't altogether warranted. Fast track is a nice win for the company, but all that really matters in this case is the data.

Now what

Fortunately, investors shouldn't have to wait all that long to know whether or not CTX001 is a viable therapy. The lowdown is that TDT requires blood transfusions every few weeks to be effectively managed. As such, a slowdown in the rate of transfusions in CTX001-treated patients should be evident fairly quickly -- perhaps within a matter of months. The therapy's side effect profile will undoubtedly take longer to properly characterize, but CTX001's efficacy shouldn't remain a mystery much longer.

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of CRISPR Therapeutics. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$61.40 (-2.79%) $-1.76
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$278.13 (-1.88%) $-5.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.